|
EXEL | Exelixis, Inc. |
|
|
EXEL | Exelixis, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.21 |
| Leverage | 23.13% |
| Market Cap | $ 10.7B |
| PE | 22.88 |
| Dividend Yield | 0.00% |
| Profit | $ 466.0m |
| Margin | 21.86% |
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.